Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

221P - Comparison of efficacy and safety of carboplatin combined with nab-paclitaxel or paclitaxel as first-line therapy for advanced thymic epithelial tumors


31 Mar 2023


Poster Display session


Yue Hao


Journal of Hepatology (2023) 18 (4S): S154-S159.


Y. Hao1, J. Si2, J. Wei3, X. Gu2, W. Wang4, Y. Zhang5, Y. Guan3, H. Huang6, C. Xu7, Z. Song3

Author affiliations

  • 1 Hangzhou/CN
  • 2 Zhejiang Chinese Medical University, hangzhou/CN
  • 3 zhejiang cancer hospital, hangzhou/CN
  • 4 Zhejiang Cancer Hospital, Hangzhou/CN
  • 5 Hangzhou Cancer Hospital, hangzhou/CN
  • 6 Shanxi Medical University, taiyuan/CN
  • 7 Nanjing University School of Medicine, jinling/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 221P


Paclitaxel/carboplatin (PC) is the standard first-line chemotherapy for advanced thymoma and thymic carcinoma. However, although nanoparticle albumin-bound (nab)-PC and PC have exhibited efficacy in various solid tumors, data for thymic epithelial tumors are lacking, including a comparison of the efficacies of nab-PC and PC.


We conducted a retrospective study to compare the efficacy and safety of nab-PC with PC in previously untreated patients with advanced thymoma and thymic carcinoma. We analyzed the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs). Cox proportional hazards regression analyses were carried out to determine the factors independently associated with survival.


Ninety-one patients were enrolled from October 2006 to September 2021. The ORRs in patients treated with nab-PC and PC were 48.8% vs 36%, respectively (P = 0.219). Among patients with thymic carcinoma, PFS differed between the nab-PC and PC groups (10.5 vs 6.3 months, P = 0.0049); however, no such difference occurred in the thymoma group (13.8 vs 12.3 months, P = 0.6948). The median OS was 27.4 months in 54 patients in thymic carcinoma, but was not reached for thymoma patients (P = 0.0024).


Nab-PC may be more effective than PC as first-line therapy in patients with advanced thymic epithelial tumors. Nab-PC could thus become an alternative regimen in patients with thymic epithelial tumors, especially thymic carcinoma.

Legal entity responsible for the study

The authors.


Tumor Research Foundation of CSCO-shiyao (Y-SY201901-0068).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.